PonatinibDevelopment of resistance: 3 case reports

被引：0

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1787卷 / 1期

关键词：

D O I：

10.1007/s40278-020-74056-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：418 / 418

相关论文

共 50 条

[41] AfatinibDiarrhoea, skin toxicity and drug resistance: 3 case reports [J].

Reactions Weekly, 2022, 1891 (1) :15-15

[42] Nivolumab/pembrolizumabDevelopment of drug resistance and nephritis: 3 case reports [J].

Reactions Weekly, 2020, 1823 (1) :275-275

[43] Erlotinib/gefitinibDevelopment of resistance to erlotinib and gefitinib: 3 case reports [J].

Reactions Weekly, 2018, 1730 (1) :136-136

[44] Ciprofloxacin/cefepimeDrug resistance and renal toxicity: 3 case reports [J].

Reactions Weekly, 2018, 1684 (1) :71-71

[45] PrednisoloneInsulin-resistance and lack of efficacy: 3 case reports [J].

Reactions Weekly, 2023, 1985 (1) :442-442

[46] AntiviralsHyperbilirubinemia, general malaise and drug resistance: 3 case reports [J].

Reactions Weekly, 2021, 1886 (1) :66-66

[47] AntiviralsTreatment failure secondary to antiviral resistance: 3 case reports [J].

Reactions Weekly, 2018, 1724 (1) :51-51

[48] Multiple drugsDevelopment of resistance and lack of efficacy: 3 case reports [J].

Reactions Weekly, 2021, 1861 (1) :211-211

[49] AmikacinTreatment failure due to acquired resistance: 3 case reports [J].

Reactions Weekly, 2015, 1555 (1) :20-20

[50] LenalidomideVarious toxicities: 3 case reports: 3 case reports [J].

Reactions Weekly, 2021, 1836 (1) :459-459

← 1 2 3 4 5 →